Buy TB500 UK For Lab Research

Product Description

TB-500 (Thymosin Beta-4) | Buy TB-500 UK | Actin-Sequestering Repair Peptide | Research Use Only

TB-500 is the synthetic research analogue of Thymosin Beta-4 (Tβ4) — a naturally occurring 43-amino acid peptide found in virtually all mammalian cells, first isolated from bovine thymus tissue and now one of the most broadly studied tissue repair and regeneration peptides in pre-clinical science. It is studied in laboratory research for its role as the major G-actin sequestering molecule in eukaryotic cells, underpinning research into wound healing, angiogenesis, cardiac tissue repair, epicardial progenitor biology, neuroprotection, skeletal muscle regeneration, and anti-inflammatory pathway modulation — available to buy in the UK from Peptides Lab UK in high-purity lyophilised form, >99% HPLC-verified purity, with batch-specific COA and fast UK dispatch for laboratory and in vitro research use only.

Distributed by Peptides Lab UK in a high-purity lyophilised format, for laboratory research use only. This compound is handled in controlled settings for in vitro and pre-clinical studies, with no applications in human or veterinary medicine. Each batch undergoes rigorous quality analysis to ensure >99% purity (HPLC verified).

What Is TB-500 (Thymosin Beta-4)?

Thymosin β4 is a low molecular weight, naturally occurring peptide that plays a vital role in the repair and regeneration of injured cells and tissues. After injury, thymosin β4 is released by platelets, macrophages, and many other cell types to protect cells and tissues from further damage — reducing apoptosis, inflammation, and microbial growth. Thymosin β4 binds to actin and promotes cell migration, including the mobilisation, migration, and differentiation of stem and progenitor cells, which form new blood vessels and regenerate tissue. It also decreases the number of myofibroblasts in wounds, resulting in decreased scar formation and fibrosis.

The beta thymosins are a family of highly conserved acidic 5 kDa peptides, originally thought to be thymic hormones. Currently, three beta thymosins are present in humans: Thymosin β4 (TB4), Thymosin β10 (TB10), and Thymosin β15 (TB15). Thymosin β4 binds and alters cytoskeletal actin filaments by sequestering actin monomers, influencing actin filament assembly and regulating migration of various cell types — including endothelial cells, myocardial cells, and epicardial progenitors. It also inhibits cellular death by activating the focal adhesion complex, resulting in Akt activation with wide-ranging effects on growth, survival, and motility.

TB-500 refers specifically to the synthetic research peptide form of Tβ4. Its molecular structure includes a blocked N-terminus through acetylation — confirmed to be essential for proper biological function — and its central actin-binding domain contains the sequence LKKTETQ, which has been independently identified as the minimal active fragment responsible for actin binding and cell migration promotion.

As a research compound, TB-500 UK is one of the most broadly studied synthetic tissue repair peptides in the published literature, with pre-clinical studies spanning dermal wound healing, corneal injury repair, cardiac biology, neurological recovery, skeletal muscle regeneration, and inflammatory pathway modulation — forming the scientific basis for multiple clinical trials conducted by RegeneRx Biopharmaceuticals.

How Does TB-500 Work?

TB-500’s primary mechanism centres on G-actin sequestration — the direct binding of monomeric (G) actin — which regulates the dynamic balance between free actin monomers and polymerised filamentous (F) actin. This seemingly simple mechanism has profound downstream consequences across virtually every tissue type, as actin dynamics are fundamental to cell migration, structural integrity, and signalling.

G-Actin Sequestration and Cytoskeletal Remodelling

TB-500 functions as the major G-actin sequestering molecule in cells, controlling actin polymerisation processes that drive cellular migration and tissue repair. The peptide’s ability to sequester G-actin maintains the pool of monomeric actin necessary for rapid filament assembly when cells need to migrate or change shape — a regulation that is essential for wound healing responses. Research has identified several active fragments within the TB-500 sequence, each with distinct biological properties.

PINCH-ILK-Akt Survival Signalling

TB-500 has been shown to form a functional complex with PINCH and integrin-linked kinase (ILK), resulting in activation of the survival kinase Akt/PKB — which is necessary for thymosin beta-4’s effects on cardiomyocyte survival, migration, and cardiac function. After coronary artery ligation in mice, TB-500 treatment resulted in upregulation of ILK and Akt activity in the heart, enhanced early myocyte survival, and improved cardiac function.

Multi-Cell Type Migration Enhancement

Research has confirmed that TB-500 accelerates the rate at which cells migrate into wounded areas — with this enhanced migration applying to keratinocytes, fibroblasts, and endothelial cells. The peptide upregulates matrix metalloproteinase (MMP) production, facilitating basement membrane degradation necessary for cellular movement — and a comprehensive review in Frontiers in Endocrinology has detailed how its actin-binding properties regulate cytoskeletal function across multiple tissue repair contexts.

Notch Pathway and Angiogenesis

TB-500 has been shown to promote angiogenesis, likely through the Notch signalling pathway, while also organising connective tissue and preventing the appearance of myofibroblasts — dual actions that distinguish it as both a pro-regenerative and anti-fibrotic research tool.

What Does TB-500 Do in Research?

In laboratory and pre-clinical settings, TB-500 / Thymosin Beta-4 has been studied across an exceptionally wide range of biological systems. Research has examined its role in:

• G-actin sequestration and cytoskeletal dynamics in cell migration studies
• Dermal wound healing — re-epithelialisation, collagen deposition, and angiogenesis
• Cardiac tissue preservation, cardiomyocyte survival, and post-MI epicardial progenitor activation
• Coronary vessel development and adult epicardial neovascularisation
• Neurological recovery — stroke model functional outcome, axonal remodelling, and oligodendrocyte progenitor recruitment
• Corneal wound healing and alkali injury repair
• Skeletal muscle regeneration in dystrophin-deficient models
• Anti-inflammatory cytokine downregulation and sepsis model research
• Stem and progenitor cell mobilisation, differentiation, and tissue homing
• AcSDKP (N-acetyl-seryl-aspartyl-lysyl-proline) generation and its role as a downstream pro-angiogenic mediator

TB-500 and Wound Healing Research

In a rat full thickness wound model, topical or intraperitoneal addition of Tβ4 increased re-epithelialisation by 42% over saline controls at 4 days, and by as much as 61% at 7 days post-wounding. Treated wounds contracted at least 11% more than controls by day 7. Increased collagen deposition and angiogenesis were observed in treated wounds, and Tβ4 stimulated keratinocyte migration 2–3-fold in Boyden chamber assays at concentrations as low as 10 pg — results that identified Tβ4 as a potent, multi-mechanism wound healing factor.

TB-500 and Cardiac Repair Research

Research confirmed that the secreted peptide Thymosin beta-4 could inhibit myocardial cell death, stimulate vessel growth, and activate endogenous cardiac progenitors by returning the adult heart to an embryonically active programme — with epicardial thickening and increases in myocardial and epicardial progenitors observed both with and without infarction, indicating that the reactivation process is independent of injury.

TB-500 and Epicardial Progenitor Biology

Research identified Thymosin beta-4 as essential for all aspects of coronary vessel development in mice, demonstrating that Tβ4 stimulates significant outgrowth from quiescent adult epicardial explants, restoring pluripotency and triggering differentiation of fibroblasts, smooth muscle cells, and endothelial cells — with knockdown of Tβ4 in the heart producing significant reduction in the pro-angiogenic cleavage product AcSDKP.

TB-500 and Neurological Recovery Research

In a rat embolic stroke model, administration of Tβ4 at 24 hours after middle cerebral artery occlusion and every 3 days for 4 additional doses produced significant improvement in functional neurological outcome — with evidence of axonal remodelling at the ischaemic boundary, increased oligodendrocyte precursor cells in the SVZ, striatum, and corpus callosum, and increased mature oligodendrocytes — suggesting a mechanism involving axonal remodelling rather than direct neuroprotection.

TB-500 and Corneal Research

Studies in animal models of corneal alkali injury demonstrated that Tβ4 promotes corneal wound healing and decreases inflammation in vivo, contributing to the scientific foundation for ongoing corneal injury clinical trials conducted by RegeneRx Biopharmaceuticals.

What Do Studies Say About TB-500?

TB-500 / Thymosin Beta-4 has one of the most extensive published research profiles of any synthetic repair peptide, with peer-reviewed studies spanning wound biology, cardiac science, neurology, and clinical trial data.

TB-500 and the Multicenter Clinical Trial Programme

Studies in various animal models of disease and repair have provided the scientific foundation for ongoing dermal, corneal, and cardiac wound repair multicenter clinical trials. Tβ4 has multiple biological activities that include downregulation of inflammatory chemokines and cytokines, and promotion of cell migration, blood vessel formation, cell survival, and stem cell maturation — all contributing to the multiple wound healing properties observed in animal studies.

The Scientifically Significant Cardiac Debate

The epicardial cardiomyocyte differentiation question — whether TB4 pretreatment can reprogram epicardium-derived progenitor cells into cardiomyocytes following MI — has been the subject of active scientific debate, with initial reports in small animal models supporting differentiation and subsequent lineage-tracing studies failing to confirm this conclusion. This productive scientific controversy has focused attention on what TB4 does reliably achieve: epicardial thickening, increased coronary capillary density, cardiomyocyte survival, and improved haemodynamic function — all consistently observed across studies regardless of the differentiation debate.

TB-500 and Endothelial Progenitor Cell Research

A pilot human study investigating autologous Tβ4-pretreated endothelial progenitor cell transplantation in patients with acute STEMI found that the approach appeared feasible and safe, with potentially beneficial effects on exercise capacity and left ventricular function at 6 months — establishing TB4 pretreatment of EPCs as a research approach of clinical interest.

TB-500 and Actin Biology — The Foundational Research

Thymosin beta-4 binds and alters the cytoskeletal actin filaments by sequestering actin monomers, influencing actin filament assembly and regulating migration of multiple cell types including endothelial cells, myocardial cells, and epicardial progenitors — with Akt activation via the ILK/PINCH/focal adhesion complex pathway confirmed as the primary survival signalling mechanism downstream of its actin-binding activity.

Key cited studies:

• Philp D et al. (1999) — Thymosin Beta-4 Accelerates Wound Healing — FASEB J. PubMed ID: 10469335
• Goldstein AL et al. (2012) — Thymosin β4: A Multi-Functional Regenerative Peptide — Basic Properties and Clinical Applications — Expert Opin Biol Ther 12(Suppl1):S37–51. PubMed ID: 22074294
• Smart N et al. (2007) — Thymosin Beta-4 Induces Adult Epicardial Progenitor Mobilisation and Neovascularisation — Nature 445(7124):177–182. PubMed ID: 17108969
• Bock-Marquette I et al. (2004) — Thymosin Beta-4 Is Cardioprotective After Myocardial Infarction — Nature 432(7016):466–472. PubMed ID: 17600280
• Kleiman NS et al. (2015) — Randomised Placebo-Controlled Single and Multiple Dose Study of IV Thymosin Beta-4 in Healthy Volunteers — RegeneRx Phase 1 Trial — NCT01311518
• Mak YT et al. (2011) — Thymosin β4 Improves Functional Neurological Outcome in Rat Embolic Stroke Model — PMC2907184
• Kleinman HK & Sosne G (2016) — Thymosin β4 Promotes Dermal Healing — Vitam Horm 102:251–275. PubMed ID: 27013258
• Smart N et al. (2006) — Thymosin Beta-4: Essential for Coronary Vessel Development — Ann N Y Acad Sci. PubMed ID: 17495252

TB-500 vs Related Tissue Repair Research Peptides

TB-500’s combination of universal tissue expression, fundamental actin biology, multi-system repair activity, anti-fibrotic myofibroblast suppression, and the breadth of its published clinical and pre-clinical research makes it one of the most versatile and comprehensively validated synthetic repair peptides available for laboratory research.

Quality & Purity Assurance

Every batch of TB-500 from Peptides Lab UK is:

• >99% pure — HPLC and mass spectrometry verified
• Supplied with a full Certificate of Analysis (COA) on request
• Lyophilised powder for maximum stability and long shelf life
• Manufactured under strict, controlled laboratory conditions
• Consistent batch-to-batch quality for reproducible research results

Buy TB-500 UK — Product Specifications

TB-500 Research Applications

TB-500 (Thymosin Beta-4) peptide UK is supplied strictly for the following in vitro and pre-clinical research uses:

• G-actin sequestration, actin polymerisation dynamics, and cytoskeletal remodelling studies
• Dermal wound healing — re-epithelialisation, collagen deposition, and MMP upregulation
• Cardiac tissue preservation, ILK/PINCH/Akt survival pathway, and post-MI epicardial progenitor activation
• Coronary vessel development and adult epicardial neovascularisation via AcSDKP generation
• Neurological recovery — stroke model functional outcome, axonal remodelling, and OPC recruitment
• Corneal wound healing and alkali injury repair research
• Skeletal muscle regeneration and dystrophin-deficient muscle biology
• Anti-inflammatory pathway research — cytokine and chemokine downregulation
• Stem and progenitor cell mobilisation, migration homing, and differentiation studies
• Myofibroblast suppression and anti-fibrotic pathway investigations
• LKKTETQ active fragment and TB-500 structure–activity relationship (SAR) research

Why Buy TB-500 from Peptides Lab UK?

Peptides Lab UK is a trusted UK peptides supplier, providing research-grade compounds verified by independent HPLC testing. When you buy TB-500 in the UK from us, you receive:

• >99% purity, HPLC and MS verified, third-party tested
• Full COA documentation per batch
• Fast same-day UK dispatch with tracked delivery
• Competitive pricing with bulk research discounts available
• Trusted by researchers across the UK and Europe

Research Disclaimer All products supplied by Peptides Lab UK are intended strictly for in vitro laboratory research and scientific study use only. They are not intended for human consumption, veterinary use, or any medical or therapeutic application. TB-500 (Thymosin Beta-4) is not a licensed medicine or drug and has not been approved by the MHRA, FDA, or any regulatory authority for use in humans or animals in this form. While Thymosin Beta-4 has been investigated in Phase 1 and Phase 2 clinical trials by RegeneRx Biopharmaceuticals, no licensed therapeutic approval has been granted. All research citations on this page relate to pre-clinical studies and peer-reviewed pharmacological research and do not constitute a claim of safety or therapeutic efficacy. Peptides Lab UK accepts no liability for any misuse of research compounds. By purchasing, you confirm that you are a qualified researcher and that the product will be used solely within a controlled laboratory environment in compliance with all applicable UK laws, regulations, and institutional guidelines.